Lothian Health Board Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2003
NCT00326352
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Lothian Health Board

Active Ingredients

Drugs in Phase 3 Trials (1)

ondansetron (zofran) (1 trial)

Drugs in Other Trials (2)

propofol (diprivan) (1 trial)

remifentanil (ultiva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diarrhea (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3